DPCP for Skin Diseases
Trial Summary
What is the purpose of this trial?
The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.
Research Team
Craig Elmets, MD
Principal Investigator
Univ. of Alabama at Birmingham
Tyler Downing, MD
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for individuals aged 18-35 who understand the study's requirements and risks, and can consent to participate. It excludes those with certain skin pigment disorders, a history of skin cancer or photosensitivity, high sun exposure risk including tanning parlors, darker skin types (Fitzpatrick IV-VI), immune system conditions or drug use affecting immunity, and women who are pregnant or lactating.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are stratified into Control, Non-UVB, or UVB groups and receive treatments with DPCP and/or UVB exposure
Follow-up
Participants are monitored for safety and effectiveness after treatment, including measurement of skin bifold thickness
Treatment Details
Interventions
- Diphenylcyclopropenone (DPCP)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor